Drug Companies give tiered roayalties to develpment of new drugs
IT STARTS IN THE MOLECULE-
FROM FIERCE PUBLICATIONS
Harvard, like any biotech operating in the deals sphere, does care about the numbers and what they say about the potential value of the work being done. And even if it can't spell out all the figures, Kohlberg's group carefully noted that Merck's package includes tiered royalties.
Kohlberg and the Harvard Square squad are also coy about just what Merck is getting in the deal. There are some trial-ready small molecules that "inhibit enzymes that regulate the transcription of key genetic programs that are altered in AML and other cancers." But that's about as far as they want to go.
Harvard officials, though, tipped their hand last fall with a report on Shair's work that we wrote up in FierceBiotechResearch. Shair's lab synthesized a molecule called cortistatin A, which was extracted from sea sponges. The molecule inhibits a pair of kinase twins--CDK8 and CDK19--and the team came up with a three-dimensional structure that they say narrowed the drug's focus to a very limited set of targets--reducing the chances of off-target toxicity. The strategy turns up the activity of genes involved in AML cells, restoring them to their normal identity and preventing further growth. And they've been crafting new molecules that can do the same work even better, building them in a way that should ease manufacturing processes during clinical development.
Add it all up, Harvard said in September, and you had a nice package deal waiting for a drug developer ready to take it into human studies. Six months later, Merck--which has shown just how aggressive it can be in development--won the bid.
